A novel tetradentate ruthenium(II) complex containing tris(2- pyridylmethyl)amine (tpa) as an Inhibitor of Beta-Amyloid Fibrillation

Current Alzheimer Research

Volumn 12, Issue 5, 2015, Pages 434-438

  Chan, Sharon Lai Fung ^a   Lu, Lihua ^b   Lam, Tsz Lung ^a   Yan, Siu Cheong ^a   Leung, Chung Hang ^c   Ma, Dik Lung ^b  

^a HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

^b HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

^c University of Macau   (Macao)

Author keywords

2 acetylbenzo b thiophen 3 olate; Alzheimer's disease; Beta amyloid; Ruthenium(II); Tris(2 pyridylmethyl)amine

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; NOOTROPIC AGENT; PYRIDINE DERIVATIVE; RUTHENIUM COMPLEX; AMYLOID BETA PROTEIN; NEUROPROTECTIVE AGENT; PEPTIDE FRAGMENT; PROTEIN AGGREGATE; RUTHENIUM; TRIS(2-PYRIDYLMETHYL)AMINE;

ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CRYSTAL STRUCTURE; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTON NUCLEAR MAGNETIC RESONANCE; TRANSMISSION ELECTRON MICROSCOPY; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; METABOLISM; SPECTROSCOPY; SYNTHESIS;

AMYLOID BETA-PEPTIDES; MICROSCOPY, ELECTRON, TRANSMISSION; MOLECULAR STRUCTURE; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; PROTEIN AGGREGATES; PYRIDINES; RUTHENIUM; SPECTRUM ANALYSIS;

EID: 84930911730     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205012666150504150726     Document Type: Article

References (52)

1. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-356 (2002).
2. Ballatore C, Lee VMY, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 8: 663-672 (2007).
3. Alzheimer's Association. 2014 Alzheimer's disease facts and figures. Alzheimer Dement 10: e47-e92 (2014).
4. Hampel H, Prvulovic D, Teipel S, Jessen F, Luckhaus C, Frolich L, et al. The future of Alzheimer's disease: The next 10 years. Prog Neurobiol 95: 718-728 (2011).
5. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β - peptide. Nat Rev Cell Biol 8: 101-112 (2007).
6. Reed MN, Hofmeister JJ, Jungbauer L, Welzel AT, Yu C, Sherman MA. Cognitive effects of cell-derived and synthetically derived Aβ oligomers. Neurobiol Aging 32: 1784-1794 (2011).
7. Portelius E, Zetterberg H, Andreasson U, Brinkmalm G, Andreasen N, Wallin A, et al. An Alzheimer's disease-specific β -amyloid fragment signature in cerebrospinal fluid. Neurosci Lett 409: 215- 219 (2006).
8. Patel V, Zhang X, Tautiva NA, Nyabera1 AN, Owa OO, Baidya M, et al. Small Molecules and alzheimer's disease: misfolding, metabolism and imaging. Curr Alzheimer Res 12(5): 445-460 (2015).
9. Yang W, Wong Y, Ng OTW, Bai LP, Kwong DWJ, Ke Y, et al. Inhibition of β-amyloid peptide aggregation by multifunctional carbazole-based fluorophores. Angew Chem Int Ed 51: 1804-1810 (2012).
10. Cohen T, Frydman-Marom A, Rechter M, Gazit E. Inhibition of amyloid fibril formation and cytotoxicity by hydroxyindole derivatives. Biochemistry 45: 4727-4735 (2006).
11. Hong HS, Rana S, Barrigan L, Shi A, Zhang Y, Zhou F, et al. Inhibition of Alzheimer's amyloid toxicity with a tricyclic pyrone molecule in vitro and in vivo. J Neurochem 108: 1097-1108 (2009).
12. Reinke AA, Gestwicki JE. Structure-activity relationships of amyloid β-aggregation inhibitors based on curcumin: influence of linker length and flexibility. Chem Biol Drug Des 70: 206-215 (2007).
13. Reinke AA, Ung PMU, Quintero JJ, Carlson HA, Gestwicki JE. Chemical probes that selectively recognize the earliest Aβ oligomers in complex mixtures. J Am Chem Soc 132: 17655-17657 (2010).
14. Razavi H, Palaninathan SK, Powers ET, Wiseman R, Purkey HE, Mohamedmohaideen NN, et al. Bisaryloxime ethers as potent inhibitors of transthyretin amyloid fibril formation. J Med Chem 48: 1576-1587 (2005).
15. Mishra R, Bulic B, Sellin D, Jha S, Waldmann H, Winter R. Smallmolecule inhibitors of islet amyloid polypeptide fibril formation. Angew Chem Int Ed 47: 4679-4682 (2008).
16. Ho S-L, Poon C-Y, Lin C, Yan T, Kwong DW-J, Yung KK-L, et al. Inhibition of β-amyloid aggregation by albiflorin, aloeemodin and neohesperidin and their neuroprotective effect on primary hippocampal cells against β -amyloid induced toxicity. Curr Alzheimer Res 12(5): 424-433 (2015).
17. Arai T, Araya T, Sasaki D, Taniguchi A, Sato T, Sohma Y, et al. Rational design and identification of a non-peptidic aggregation inhibitor of amyloid-β based on a pharmacophore motif obtained from cyclo[-Lys-Leu-Val-Phe-Phe-]. Angew Chem Int Ed 53: 8236-8239 (2014).
18. Taylor M, Moore S, Mayes J, Parkin E, Beeg M, Canovi M, et al. Development of a proteolytically stable retro-inverso peptide inhibitor of β -amyloid oligomerization as a potential novel treatment for Alzheimer's disease. Biochemistry 49: 3261-3272 (2010).
19. Gordon DJ, Sciarretta KL, Meredith SC. Inhibition of β -amyloid (40) fibrillogenesis and disassembly of β -amyloid (40) fibrils by short β -amyloid congeners containing N-methyl amino acids at alternate residues. Biochemistry 40: 8237-8245 (2001).
20. Yamin G, Ruchala P, Teplow DB. A peptide hairpin inhibitor of amyloid β -protein oligomerization and fibrillogenesis. Biochemistry 48: 11329-11331 (2009).
21. Li M, Yang X, Ren J, Qu K, Qu X. Using graphene oxide high near-infrared absorbance for photothermal treatment of Alzheimer's disease. Adv Mater 24: 1722-1728 (2012).
22. Yoo SI, Yang M, Brender JR, Subramanian V, Sun K, Joo NE, et al. Inhibition of amyloid peptide fibrillation by inorganic nanoparticles: functional similarities with proteins. Angew Chem Int Ed 50: 5110-5115 (2011).
23. Linse S, Cabaleiro-Lago C, Xue WF, Lynch I, Lindman S, Thulin E, et al. Nucleation of protein fibrillation by nanoparticles. Proc Natl Acad Sci 104 : 8691-8696 (2007).
24. Xiao L, Zhao D, Chan WH, Choi MMF, Li HW. Inhibition of β1- 40 amyloid fibrillation with N-acetyl-L-cysteine capped quantum dots. Biomaterials 31: 91-98 (2010).
25. Lee HH, Choi TS, Lee SJC, Lee JW, Park J, Ko YH, et al. Supramolecular inhibition of amyloid fibrillation by cucurbit[7]uril. Angew Chem Int Ed 53: 1-6 (2014).
26. Geng J, Li M, Ren J, Wang E, Qu X. Polyoxometalates as inhibitors of the aggregation of amyloid β peptides associated with Alzheimer's disease. Angew Chem Int Ed 50: 4184-4188 (2011).
27. Zhai P, Xia C-L, Tan J-H, Li D, Ou T-M, Huang S-L, et al. Syntheses and evaluation of asymmetric curcumin analogues as potential multifunctional agents for the treatment of Alzheimer's disease. Curr Alzheimer Res 12(5): 403-414 (2015).
28. Kochi A, Lee HJ, Vithanarachchi SM, Padmini V, Allen MJ, Lim MH. Inhibitory activity of curcumin derivatives towards metal-free and metal-induced amyloid-β aggregation. Curr Alzheimer Res 12(5): 415-423 (2015).
29. Wong, C-Y, Chung L-H, He B, Leung C-H, Ma D-L. Dual inhibition and monitoring of β-amyloid fibrillation by a luminescent iridium(III) complex. Curr Alzheimer Res 12(5): 439- 444 (2015).
30. Ma D-L, Ma VP-Y, Chan DS-H, Leung K-H, He H-Z, Leung C-H. Recent advances in luminescent heavy metal complexes for sensing. Coord Chem Rev 256: 3087-3113 (2012).
31. Yam VWW, Wong KMC. Luminescent metal complexes of d6, d8 and d10 transition metal centres. Chem Commun 47: 11579-11592 (2011).
32. Kenche VB, Hung LW, Perez K, Volitakes I, Ciccotosto G, Kwok J, et al. Development of a platinum complex as an anti-amyloid agent for the therapy of Alzheimer's disease. Angew Chem Int Ed 52: 3374-3378 (2013).
33. Barnham KJ, Kenche VB, Ciccotosto GD, Smith DP, Tew DJ, Liu X, et al. Platinum-based inhibitors of amyloid-β as therapeutic agents for Alzheimer's disease. Proc Natl Acad Sci USA 105: 6813-6818 (2008).
34. Kumar A, Moody L, Olaivar JF, Lewis NA, Khade RL, Holder AA, et al. Inhibition of Aβ42 peptide aggregation by a binuclear ruthenium(II)-platinum(II) complex: potential for multimetal organometallics as anti-amyloid agents. ACS Chem Neurosci 1: 691-701 (2010).
35. Heffern MC, Velasco PT, Matosziuk LM, Coomes JL, Karras C, Ratner MA, et al. Modulation of amyloid-β aggregation by histidine- coordinating cobalt(III) schiff base complexes. ChemBio- Chem 15: 1584-1589 (2014).
36. Man BYW, Chan HM, Leung CH, Chan DSH, Bai LP, Jiang ZH, et al. Group 9 metal-based inhibitors of β-amyloid(1-40) fibrillation as potential therapeutic agents for Alzheimer's disease. Chem Sci 2: 917-921 (2011).
37. Valensin D, Anzini P, Gaggelli E, Gaggelli N, Tamasi G, Cini R, et al. fac-{Ru(CO)3}2+ selectively targets the histidine residues of the β-amyloid peptide 1-28. implications for new Alzheimer's disease treatments based on ruthenium complexes. Inorg Chem 49: 4720- 4722 (2010).
38. Hayne DJ, Lim SC, Donnelly PS. Metal complexes designed to bind to amyloid-β for the diagnosis and treatment of Alzheimer's disease. Chem Soc Rev 43: 6701-6715 (2014).
39. Gill MR, Thomas JA. Ruthenium (II) polypyridyl complexes and DNA-from structural probes to cellular imaging and therapeutics. Chem Soc Rev 41: 3179-3192 (2012).
40. Suss-Fink G. Arene ruthenium complexes as anticancer agents. Dalton Trans 39: 1673-1688 (2010).
41. Vyas NA, Bhat SS, Kumbhar AS, Sonawane UB, Jani V, Joshi RR, et al. Ruthenium(II) polypyridyl complex as inhibitor of acetylcholinesterase and Aβ aggregation. Eur J Med Chem 75: 375- 381 (2014).
42. He L, Wang X, Zhao C, Wang H, Du W. Ruthenium complexes as novel inhibitors of human islet amyloid polypeptide fibril formation. Metallomics 5: 1599-1603 (2013).
43. Kraft SS, Bischof C, Loos A, Braun S, Jafarova N, Schatzschneider U. A [4+2] Mixed ligand approach to ruthenium DNA metallointercalators [Ru(tpa)(N-N)](PF6)2 Using a Tris(2- pyridylmethyl)amine (tpa) capping ligand. J Inorg Biochem 103: 1126-1134 (2009).
44. Weisser F, Hohloch S, Plebst S, Schweinfurth D, Sarkar B. Ruthenium complexes of tripodal ligands with pyridine and triazole arms: subtle tuning of thermal, electrochemical, and photochemical reactivity. Chem Eur J 20: 781-793 (2014).
45. Schafer S, Becker J, Beitat A, Wurtel C. Investigation of chromium complexes with a series of tripodal ligands. Z Anorg Allg Chem 639: 2269-2275 (2013).
46. Nagel C, McLean S, Poole RK, Braunschweig H, Kramera T, Schatzschneider U. Introducing [Mn(CO)3(tpa-κ3N)]+ as a novel photoactivatable CO-releasing molecule with well-defined iCORM intermediates-synthesis, spectroscopy, and antibacterial activity. Dalton Trans 43: 9986-9997 (2014).
47. Ma D-L, Chan DS-H, Leung C-H. Group 9 organometallic compounds for therapeutic and bioanalytical applications. Acc Chem Res 47: 3614-31 (2014).
48. Leung C-H, Zhong H-J, He H-Z, Lu L, Chan DS-H and Ma D-L. Luminescent oligonucleotide-based detection of enzymes involved with DNA repair. Chem Sci 4, 3781-95 (2013).
49. Ma D-L, He H-Z, Chan DS-H and Leung C-H. Simple DNA-based logic gates responding to biomolecules and metal ions. Chem Sci 4, 3366-80 (2013).
50. He H-Z, Chan DS-H, Leung C-H and Ma D-L. G-quadruplexes for luminescent sensing and logic gates. Nucl Acids Res 41: 4345-59 (2013).
51. Yang C, Lai SL, Chan SLF, Low KH, ChengG, Yeung KT, et al. Phosphorescent cyclometalated iridium(III) complexes that contain substituted 2-acetylbenzo[b]thiophen-3-olate ligand for red organic light-emitting devices. Chem Asian J 9: 3572-3585 (2014).
52. Kojima T, Amano T, Ishii Y, Ohba M, Okaue Y, Matsuda Y. Synhthesis and characterization of mononuclear anddinuclear ruthenium complexes with Tris(2-pyridylmethyl)amine and Tris(5- methyl-2-pyridylmethyl)amine. Inorg Chem 37: 4076-4085 (1998).